Is It Smart To Buy Huadong Medicine Co., Ltd Before It Goes Ex-Dividend - Simply Wall St
000963 Stock | 35.95 0.24 0.66% |
About 62% of Huadong Medicine's investor base is looking to short. The analysis of overall sentiment of trading Huadong Medicine Co stock suggests that many investors are alarmed at this time. The current market sentiment, together with Huadong Medicine's historical and current headlines, can help investors time the market. In addition, many technical investors use Huadong Medicine stock news signals to limit their universe of possible portfolio assets.
Huadong |
Is It Smart To Buy Huadong Medicine Co., Ltd Before It Goes Ex-Dividend Simply Wall St
Read at news.google.com
Huadong Medicine Fundamental Analysis
We analyze Huadong Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Huadong Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Huadong Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Huadong Medicine is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Huadong Medicine Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Huadong Medicine stock to make a market-neutral strategy. Peer analysis of Huadong Medicine could also be used in its relative valuation, which is a method of valuing Huadong Medicine by comparing valuation metrics with similar companies.
Peers
Huadong Medicine Related Equities
601398 | Industrial | 0.62 | ||||
601988 | Bank of China | 0.57 | ||||
600036 | China Merchants | 0.29 | ||||
600519 | Kweichow Moutai | 0.34 | ||||
601628 | China Life | 0.81 | ||||
601939 | China Construction | 0.82 | ||||
601857 | PetroChina | 0.95 | ||||
601288 | Agricultural Bank | 1.18 | ||||
600941 | China Mobile | 2.15 | ||||
300750 | Contemporary Amperex | 2.62 |
Complementary Tools for Huadong Stock analysis
When running Huadong Medicine's price analysis, check to measure Huadong Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Huadong Medicine is operating at the current time. Most of Huadong Medicine's value examination focuses on studying past and present price action to predict the probability of Huadong Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Huadong Medicine's price. Additionally, you may evaluate how the addition of Huadong Medicine to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |